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Sixty six children with SCA, descendent of African families, were categorised according to their 
degree of cerebral vasculopathy: 
 Stroke group, included  13 children with history of at least one stroke episode between ages 5 
and 13. 
 Risk group, included  29 children with high transcranial Doppler (TCD) velocities, either 
“conditional” (170 – 199 cm/s) or “high risk” (>200 cm/s), and children with silent infarcts or 
cerebral vasculopathy on magnetic resonance imaging (MRI) .  
 Control  group, included 24 children without previous history of stroke, normal TCD velocities 
and no abnormalities on MRI.   
Relevant data were collected from patients’ medical records.  
Twenty three polymorphic regions were characterised in genes related to vascular cell adhesion 
(VCAM 1, THBS 1, CD36), vascular tonus (NOS3, ET1), and inflammation (TNF α, HMOX 1) as well 
as in known globin expression modulators (HBB cluster haplotype; HBA and BCL11A genotypes). 
 Data analysis was performed using R software. 
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Table I. Association between candidate gene variants and stroke risk in SCA 
 
The genetic variants showed in Table I might modulate cerebral vasculopathy 
development (stroke/risk) due to their modifier effect on gene expression and  on 
their corresponding protein product biological activities. Several mechanisms are 
involved: 
 Cell vascular adhesion – genetic variants related with an increased synthesis of 
vascular cell adhesion molecules (i.e., rs1409419_allele T of VCAM 1 gene promoter; 
Table I) promote RBCs and leukocyte adhesion to endothelium, as well platelet 
aggregation,  and are associated  with  cerebral vasculopathy  development and 
stroke  events.  
 Vascular tonus – The endothelial nitric oxide synthase has been implicated in 
vasculopathy and stroke. In fact, production of Nitric Oxide (NO) is of major 
importance to maintain a correct vascular tonus, which in SCA is skewed towards 
vasoconstriction, as a result of a net resistance to NO. Therefore, genetic variants in 
NOS 3  (Table I) that further decrease basal NO levels can be very deleterious  to  SCA 
patients (Fig. 2).  
 
 
 
 
 
 
In addition, a decreased rate of transcription of HMOX 1  due to the rs3074372_allele 
L (Table I) leads to lower circulating heme oxygenase 1 and consequently free heme is    
         not adequately removed and further scavenges NO molecules.  
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Sickle cell anemia (SCA) is an autosomal recessive disease caused by the mutation HBB:c.20A>T in beta-globin gene. This missense mutation gives rise to a hemoglobin variant (Hb S)  that, 
upon deoxygenation, polymerises inside the red blood cells (RBCs) leading to abnormal sickle-shaped cells.  Sickle RBCs are less deformable and stickier than normal, causing vessel 
obstruction and local ischemia. Also, the polymerization of HbS is accompanied by RBC membrane damage and dehydration, accelerating hemolysis. Thus, the clinical manifestations of the 
disease derive essentially from two phenomena - hemolysis and vaso-occlusion. However, their variability and severity are modulated by environmental and genetics factors  (1). 
One of the most devastating complication affecting children with SCA is cerebral vasculopathy (overt stroke and silent infarcts). Overt stroke occurs in about 11% of those children before the 
age of 20 (2, 3). However, its pathophysiology is complex and the underlying mechanisms remain largely unknown (Fig. 1). Therefore, in this study, the main objective was to identify genetic 
modulators of stroke in the context of SCA in paediatric patients.  
Fig. 1 - Pathophysiology of stroke in SCA.  
The abnormal adherence (1) and high rate hemolysis (2) of the 
sickle RBCs are the basis for the development of cerebrovascular 
disease in patients with SCA. The activated endothelium expresses 
a great amount of endothelium-specific molecules, promoting 
leukocyte adhesion (3), platelet aggregation (6), and increased 
release of the vasoconstrictor endothelin (ET 1). The scavenging of 
NO by cell-free hemoglobin further increases vasomotor tone (4). 
Tissue remodeling due to smooth-muscle cells and fibroblasts 
proliferation in the intimal layer (5) leads to luminal narrowing, 
followed by vasculopathy (7) and occlusion (8).  
Adapted from Switzer et al., 2006 (4). 
 Hemolysis – Lactate dehydrogenase (LDH) is released from RBCs during the hemolytic process 
and constitutes a marker for the magnitude of hemoglobin and arginase release (marker of 
hemolysis). We have found that higher LDH levels are associated with Risk group (Table II; Fig. 3), 
which means that this proximal hemolytic marker is closely related with the initial stage of 
cerebral vasculopathy.  
In conclusion, our findings reinforce the relevance of vascular tonus, vascular cell adhesion, 
hemolysis rate and ultimately NO bioavailability in modulating SCA stroke development and 
provide the first evidence of a protective role of fetal hemoglobin against stroke occurrence.  
* False-discovery-rate corrected p-values; OR – Odds Ratio; VNTR – variable number  of tandem repeat; LDH – lactate dehydrogenase; 4x – alleles 4b or 4c;  
S – Small nº of repeats (n≤ 26), M – medium nº of repeats (27≤ n ≤ 34), L – long nº of repeats (n≥ 35)  
 
Table II. Association between biochemical parameters and stroke risk in SCA 
 
Fig. 2 - Decreased NO bioavailability in SCA. 
Intravascular hemolysis reduces nitric oxide bioactivity 
by releasing hemoglobin and arginase, which inactivate 
NO and consume plasma L-arginine (NO precursor), 
respectively. Additionally , NO  is consumed by reactions 
with reactive oxygen species highly produced in SCA. 
The resulting decrease in NO is associated with leg 
ulceration, priapism, pulmonary hypertension and 
possibly non-hemorrhagic stroke.   
Adapted from Kato, et al., 2007 (5). 
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Fig. 3 -  Distribution of LDH 
values in the three phenotype 
groups.  
The boxplots revealed a clear 
difference between LDH values 
in Risk group when compared to 
Stroke or Control groups.  
